How rifampicin affects a new oral medicine
Treatments studied
Part of Cancer, Skin clinical trials.
This study checks how your body handles a new medicine when it is taken with rifampicin, a common antibiotic. It helps researchers understand if the new medicine is safe and how it interacts with other drugs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 55 years old.
- You are in good overall health, with no major medical conditions.
- Your weight is at least 50 kg (if male) or 45 kg (if female), with a BMI between 19 and 28.
- You have not used any prescription drugs, herbal remedies, or supplements recently.
- You are willing to avoid smoking, alcohol, and caffeine during the study.
- If you are capable of becoming pregnant, you agree to use highly effective birth control and not donate eggs or sperm.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HRS-6209 combined with other treatments for people with breast cancer that has worsened after previous therapy. It aims to find a more effective way to control the cancer.
This study checks how other medicines or foods affect the RSS0343 tablet in healthy adults. Participating helps researchers make the drug safer and more effective for future patients.
This study checks if a new oral drug, MDR-001, interacts safely with two common medicines (rifampin and itraconazole) when taken together. It's for healthy volunteers, and the results will help guide dosing for future patients.
This trial tests a new drug called HS-10504 in healthy adults to see how the body processes it. It is an early-phase study that helps determine safe dosing.
This trial tests whether higher or standard doses of the antibiotic rifampicin work better for treating pulmonary tuberculosis (a lung infection). You may benefit if you are starting TB treatment and have not had a bad reaction to rifampicin before.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.